Far Infrared & Systemic Sclerosis
RELAX SAUNAS · CLINICAL SCIENCE REVIEW
Far Infrared Therapy and Systemic Sclerosis
A vascular-first review of thermal evidence in scleroderma, with explicit boundaries on fibrosis and organ claims.
IN THIS REVIEW
Abstract
Background. Systemic sclerosis (SSc) is an autoimmune connective tissue disease defined by the triad of microvascular injury, immune activation, and progressive fibrosis of skin and internal organs (Denton & Khanna 2017). Raynaud’s phenomenon (RP) is nearly universal and is typically the first manifestation; digital ulcers (DU) and hand contractures are major sources of disability.
Evidence. The literature cited in this review does not include a controlled trial of far infrared (FIR) sauna in SSc. The most direct infrared evidence uses water-filtered near-infrared A (wIRA) applied to the hands, which was reported effective for SSc-associated RP (Foerster et al. 2005) and, in a 2026 randomized trial, added modest, short-term improvements in pain and RP duration to iloprost therapy (Schulz et al. 2026). Supervised Waon therapy (FIR dry-sauna protocols) has been associated with DU healing only in single case reports (Nishijima & Inaoki 2013). Adding heat to hand exercise reduced pain in one RCT (Mısırcı et al. 2026) but conferred no mobility benefit over lukewarm water in another (Kristensen et al. 2019). A 2,243-patient cohort showed a U-shaped relationship between ambient temperature and RP severity, with worsening above 25°C (Virgili-Gervais et al. 2024).
Positioning. FIR is not a disease-modifying therapy for SSc and has no demonstrated effect on fibrosis or organ involvement. Whether sauna is appropriate requires an individual assessment by the treating rheumatologist, including cardiopulmonary and renal risks. A safe or effective home sauna dose for SSc is not established by these studies.
1. Introduction
Systemic sclerosis is classified as limited cutaneous (lcSSc), with skin thickening distal to the elbows and knees, or diffuse cutaneous (dcSSc), with proximal and truncal involvement and a higher early risk of internal organ disease. Its pathogenesis begins with endothelial injury and obliterative microvasculopathy, followed by immune activation and fibroblast-to-myofibroblast transition driven by TGF-β and related pathways, with excess collagen deposition (Denton & Khanna 2017).
Raynaud’s phenomenon affects more than 95% of patients and reflects both exaggerated vasospasm and structural vascular damage. Digital ulcers occur in roughly half of patients over the disease course. Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of SSc-related death, and scleroderma renal crisis remains a medical emergency. Management is organ-based: vasodilators (calcium channel blockers, PDE5 inhibitors, intravenous prostanoids, endothelin receptor antagonists), immunosuppression for skin and lung disease, antifibrotic therapy for ILD, and hand therapy for function.
Patients with SSc are routinely advised to keep their whole body warm. A frequent question is whether a sauna can extend that advice. Because the dominant SSc lesion is vascular and FIR has well-characterized endothelial effects, a vascular-first framing is the most defensible starting point, while fibrosis and organ disease must be addressed with explicit boundaries.
2. Temperature and Raynaud’s Phenomenon
2.1 Warmth helps, within a window
In the Scleroderma Patient-centered Intervention Network (SPIN) cohort, 20,233 self-reported RP severity scores from 2,243 patients were linked to local outdoor temperature (Virgili-Gervais et al. 2024). Severity peaked at 6.8/10 at −25°C and declined with warming, most steeply between 5°C and 25°C, reaching a nadir of 2.6 at 25°C. Above 25°C, severity rose again, to 3.5 at 35°C and 5.6 at 40°C.
These are ambient weather data and cannot be transferred directly to brief sauna exposure. They nevertheless carry a practical message for thermal therapy in SSc: steady, comfortable warmth is associated with fewer symptoms, and higher heat is not automatically better. Session temperature and duration should be conservative.
2.2 Infrared hyperthermia for SSc-associated RP
Foerster and colleagues reported that wIRA-mediated hyperthermia was effective in SSc-associated RP, with outcomes including fingertip rewarming after cold challenge, a clinical activity score, skin thickness, and joint pain (Foerster et al. 2005). The report appeared as a short communication with methods in an online supplement; sample size and effect estimates should be confirmed from the full text before quantitative use.
In 2026, a randomized controlled trial tested locally applied wIRA as an adjunct to intravenous iloprost and CO₂ hand baths in SSc with severe RP (Schulz et al. 2026). The add-on was safe and produced modest, short-term improvements in pain and RP attack duration. The authors characterize the effects as exploratory and requiring confirmation. A related randomized trial of serial locoregional wIRA (DRKS00021098, n=42) is registered as completed.
Two points limit transfer to FIR sauna. First, wIRA is near-infrared A (approximately 780–1400 nm), which penetrates more deeply than FIR (approximately 4–14 µm) and was delivered locally to the hands. Second, both studies applied infrared alongside established vasoactive therapy. They support the biological plausibility of infrared warming in SSc vasculopathy; they do not test whole-body FIR.
3. Digital Ulcers
Single case reports describe healing of SSc digital ulcers with repeated Waon therapy (Nishijima & Inaoki 2013), including a refractory ulcer reported in 2021 (J Cardiol Cases 2021). Waon is a supervised warming protocol developed in Kagoshima, usually followed by warm rest. The 2021 case used a 45°C sauna for 15 minutes followed by 30 minutes of warm rest, alongside wound care, antibiotics, and vascular procedures. A case report cannot isolate the effect of sauna from these other treatments. A systematic review of locoregional DU treatments excluded Waon therapy because evidence was limited to a single report, and graded light-based approaches as low-level evidence (Costedoat et al. 2021).
Supporting plausibility comes from adjacent work. Repeated Waon thermal therapy up-regulated eNOS and augmented angiogenesis in a mouse hindlimb ischaemia model (Akasaki et al. 2006), and improved limb perfusion with healing of ischaemic ulcers in patients with peripheral arterial disease (Tei et al. 2007). PAD is a macrovascular disease, and SSc DU arise from microvascular obliteration, often with digital artery involvement; the analogy is mechanistic. Waon protocols, clinical monitoring, and accompanying treatments differ from consumer sauna use, so identical outcomes should not be assumed.
4. Hand Function: Heat as an Adjunct to Exercise
Hand contractures, reduced finger-to-palm closure, and grip weakness drive much of SSc disability. Exercise is the consistent active ingredient. In a randomized single-blind trial of 40 patients with hand dysfunction, both exercise alone and exercise plus paraffin improved Cochin hand function, HAMIS, and grip strength over 12 weeks; the only between-group difference was lower pain with paraffin (Mısırcı et al. 2026). In a larger randomized trial (n=90, 56 completers), warming hands with paraffin before exercise produced no greater improvement in hand mobility than warming them in lukewarm water, with gains in both arms maintained at 12 months (Kristensen et al. 2019).
A non-randomised controlled study of three weeks of intensive hand therapy, including 42°C hand mud baths, whirlpool, massage, and stretching, found sustained improvement in HAQ-DI and DASH at six months only in the hand-therapy group, without serious adverse events or new digital ulcers; between-group differences in change scores were not significant (Horváth et al. 2017). Taken together, the data suggest heat is a comfort and pain-modulating adjunct that may facilitate adherence to stretching; the mobility benefit comes from the exercise.
5. Mechanistic Rationale
5.1 Endothelial nitric oxide
FIR acutely increases endothelial NO production through Ca²⁺ mobilization and CaMKII-mediated phosphorylation of eNOS at Ser1179 (Park et al. 2013). In a heat-controlled three-arm randomized trial, FIR improved endothelial function and reduced arterial stiffness through NRF2-associated cytoprotective pathways (NOS3, TXNRD1, HSP70) beyond the effect of equivalent heat (Bagabir et al. 2025). FIR also induces heme oxygenase-1 and restrains TNF-α-driven endothelial adhesion molecule expression (Lin et al. 2008). Endothelial dysfunction, reduced NO bioavailability, and oxidative stress are central to SSc vasculopathy, making these the most relevant mechanisms.
5.2 Autonomic balance
Emotional stress is a recognized RP trigger. Repeated Waon sessions shifted autonomic balance toward parasympathetic predominance in patients with heart failure (Kuwahata et al. 2011). Whether this transfers to SSc is untested.
5.3 Fibrosis: an evidence gap
No study has shown that FIR reduces dermal collagen deposition, myofibroblast activation, or modified Rodnan skin score in SSc or in an SSc model. FIR is also distinct from UVA1 phototherapy (340–400 nm), which is used for sclerotic skin through induction of collagenases and is unrelated to infrared heating. Any antifibrotic claim for FIR in SSc is currently unsupported.
5.4 Evidence summary
Virgili-Gervais et al. 2024
Population / model: SSc-RP, SPIN cohort, n=2,243 (20,233 reports)
Intervention: Outdoor temperature (observational)
Key finding: RP severity fell with warming to a nadir of 2.6/10 at 25°C, then rose to 3.5 at 35°C and 5.6 at 40°C
Tier: Observational (U-shaped)
Foerster et al. 2005
Population / model: SSc-associated RP
Intervention: Water-filtered infrared A (wIRA) hyperthermia
Key finding: Reported as effective for SSc-RP; outcomes included cold-challenge rewarming, skin score, joint pain
Tier: Direct IR (near-IR), small
Schulz et al. 2026
Population / model: SSc with severe RP
Intervention: Local wIRA adjunct to iloprost + CO₂ hand baths, RCT
Key finding: Safe; modest, short-term improvement in pain and RP duration; authors call findings exploratory
Tier: Direct IR (near-IR), RCT
Nishijima & Inaoki 2013
Population / model: SSc digital ulcer, n=1
Intervention: Supervised Waon therapy (FIR dry-sauna protocols)
Key finding: Digital ulcer healing reported
Tier: Case report
J Cardiol Cases 2021
Population / model: Refractory SSc digital ulcer, n=1
Intervention: Waon therapy
Key finding: Healing of a refractory ulcer reported
Tier: Case report
Costedoat et al. 2021
Population / model: Systematic review, SSc DU locoregional therapies
Intervention: —
Key finding: Waon excluded (single report); light-based therapies low-level evidence
Tier: Review (caution)
Mısırcı et al. 2026
Population / model: SSc with hand dysfunction, n=40
Intervention: Hand exercise ± paraffin, RCT, 12 wk
Key finding: Both arms improved function; only pain (NRS) differed, favouring paraffin
Tier: Heat adjunct, RCT
Kristensen et al. 2019
Population / model: SSc, n=90 (56 completed)
Intervention: Paraffin vs lukewarm water before hand exercise, RCT
Key finding: No difference in HAMIS; both improved, maintained at 12 mo
Tier: Honest null (heat modality)
Horváth et al. 2017
Population / model: SSc with hand contractures, n=53
Intervention: 3-wk intensive hand therapy incl. 42°C mud baths, non-randomised
Key finding: Sustained HAQ/DASH gain at 6 mo in hand group; between-group difference n.s.
Tier: Multimodal, non-randomised
Akasaki et al. 2006; Tei et al. 2007
Population / model: Mouse hindlimb ischaemia; human PAD
Intervention: Repeated Waon thermal therapy
Key finding: ↑eNOS and angiogenesis (mouse); improved limb perfusion and ulcer healing (PAD)
Tier: Mechanistic / adjacent population
Park et al. 2013; Bagabir et al. 2025
Population / model: Endothelial cells; humans
Intervention: FIR
Key finding: CaMKII–eNOS-Ser1179 NO release; heat-independent NRF2/NOS3 vascular benefit
Tier: Mechanistic
FIR sauna in SSc
Population / model: —
Intervention: —
Key finding: No controlled FIR-sauna trial in SSc included in this review
Tier: Not studied
6. Safety Considerations Specific to SSc
Heat exposure produces peripheral vasodilation, increased heart rate and cardiac output, fluid loss through sweating, and transient falls in blood pressure. In SSc these responses intersect with organ complications. Patients with PAH have limited capacity to raise cardiac output and are vulnerable to syncope with vasodilation; patients with significant ILD may desaturate with increased metabolic demand; primary cardiac involvement can cause arrhythmia and conduction disease. Volume depletion is a concern in patients with gastrointestinal dysmotility, diuretic use, or renal involvement, and any new hypertension, headache, or reduced urine output requires urgent evaluation for scleroderma renal crisis rather than lifestyle measures. Open or infected digital ulcers should be dressed and managed by the treating team, and heat should never be applied directly to ulcerated or ischaemic digits.
7. Explicit Positioning
WHAT WE DO NOT CLAIM
- FIR has not been shown to modify the course of systemic sclerosis and has no demonstrated effect on skin thickening, fibrosis, or modified Rodnan skin score.
- FIR does not treat ILD, PAH, cardiac, renal, or gastrointestinal involvement.
- FIR has not been shown to heal digital ulcers; the cited clinical evidence is limited to supervised Waon case reports, including a 45°C protocol in 2021.
- Infrared RP data come from near-infrared A applied locally, adjunctive to iloprost, and should not be presented as whole-body FIR outcomes.
- FIR is not UVA1 phototherapy and does not replace vasodilator, immunosuppressive, antifibrotic, or hand therapy.
- Higher heat is not automatically better: RP severity rose at ambient temperatures above 25°C in the observational cohort; these weather data do not establish a sauna temperature threshold.
8. Open Question
The following is a proposed research design, not an active trial or a home-use recommendation.
WHAT A DEFINITIVE STUDY WOULD NEED
Population: adults with stable lcSSc and RP, without PAH, significant ILD, cardiac involvement, renal disease, or active DU.
Design: randomized comparison of low-temperature FIR sauna sessions (for example, 15–20 minutes, three times weekly for eight weeks) followed by supervised hand exercise, versus hand exercise alone.
Primary endpoints: Raynaud’s Condition Score and attack frequency and duration.
Secondary endpoints: thermographic rewarming after cold challenge, HAMIS and Cochin hand function, pain, DU incidence, and safety (blood pressure, heart rate, oxygen saturation).
Mechanistic endpoints: flow-mediated dilation or laser speckle perfusion, endothelin-1, ADMA, and markers of oxidative stress.
9. Clinical Guidance
Do not
- Recommend sauna use for patients with PAH, ILD with exertional desaturation, primary cardiac involvement, arrhythmia, or syncope.
- Use sauna in patients with prior scleroderma renal crisis, active renal disease, or new hypertension, headache, or oliguria, which require urgent evaluation.
- Apply heat directly to ulcerated, infected, or critically ischaemic digits.
- Present FIR as a substitute for vasodilator, immunosuppressive, or antifibrotic therapy, or as a treatment for skin thickening.
Discuss with the treating rheumatologist
- Whether any sauna exposure is suitable. The cited studies do not establish a safe home session length or temperature for SSc; do not treat a 10–20 minute session as a validated prescription.
- An individualized fluid plan, especially with heart or kidney disease or a fluid restriction, and stopping for dizziness, breathlessness, palpitations, or digital pain.
- Pairing sessions with the patient’s prescribed hand-stretching programme, performed while tissues are warm.
- Avoiding abrupt cold exposure after sessions; dressing warmly and rewarming gradually.
- Asking patients to record RP attacks, hand pain, and tolerance for four weeks and to share the log with their rheumatologist.
10. Conclusion
Vascular injury is an early and important feature of systemic sclerosis, and the best-supported role for warmth in SSc lies on the vascular side: core warming, symptomatic relief of Raynaud’s, and comfort that may support hand exercise. Direct infrared evidence is limited to near-infrared applied locally, and FIR sauna evidence in SSc to supervised Waon case reports with other treatments. A U-shaped temperature–symptom relationship argues for conservative settings. FIR has no demonstrated effect on fibrosis or organ disease, and its use must be screened against cardiopulmonary and renal complications. A carefully designed randomized trial in stable limited disease would resolve whether low-temperature FIR adds benefit to standard care.
EXPLORE RELAX SAUNAS
Personal warmth, with clear expectations
The studies in this review do not establish that Relax Sauna treats systemic sclerosis, Raynaud’s, digital ulcers, fibrosis, or organ involvement. Discuss suitability with your rheumatologist before considering sauna use.
References
4. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699.
Educational information only; not individualized medical advice. Far-infrared sauna is not an established treatment for systemic sclerosis or its organ complications. Consult your rheumatologist before starting a new heat practice. Proposed research doses are not home-use instructions.

